Discover
TPST
Tempest Therapeutics, Inc.
1.11
2 x 0.81
2 x 1.42
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
1.11 +0.00 (0.00%)
| Ytd | -61.32% | |
| 1y | -84.43% |
1.09
day range
1.13
1.02
52 week range
12.23
| Open | 1.09 | Prev Close | 1.11 | Low | 1.09 | High | 1.13 | Mkt Cap | 17.74M |
| Vol | 43.45K | Avg Vol | 194.38K | EPS | -5.70 | P/E | N/A | Forward P/E | -0.61 |
| Beta | -2.78 | Short Ratio | 0.39 | Inst. Own | 23.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.58 | 200-d Avg | 4.10 | 1yr Est | 18.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.37 | -0.41 | -0.04 | -10.81% |
| 2024-08-08 | 2024-06 | -0.47 | -0.42 | 0.05 | 10.64% |
| 2024-05-09 | 2024-03 | -0.44 | -0.36 | 0.08 | 18.18% |
| 2024-03-19 | 2023-12 | -0.38 | -0.34 | 0.04 | 10.53% |
| 2023-11-08 | 2023-09 | -0.55 | -0.48 | 0.07 | 12.73% |
| 2023-08-10 | 2023-06 | -0.58 | -0.54 | 0.04 | 6.90% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-13 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-21 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-06-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-07-02 | BRADY STEPHEN R | Chief Executive Officer | 46.38K | Purchase |
| 2024-06-27 | TROJANOWSKI JUSTIN | Officer | 22.17K | Purchase |
| 2024-08-11 | VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | 3.51M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 551.59K | 466.97K | 1.26% |
| 2024-09-29 | Altium Capital Management, LP | 545.00K | 461.40K | 1.25% |
| 2024-09-29 | FMR, LLC | 431.93K | 365.67K | 0.99% |
| 2024-09-29 | Geode Capital Management, LLC | 220.07K | 186.31K | 0.50% |
| 2024-09-29 | Vanguard Group Inc | 176.19K | 149.16K | 0.40% |
| 2024-09-29 | FIL LTD | 129.58K | 109.70K | 0.30% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 174.01K | 147.31K | 0.40% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 122.16K | 103.42K | 0.28% |
| 2024-10-30 | Fidelity Total Market Index Fund | 43.37K | 36.72K | 0.10% |
| 2024-10-30 | iShares Micro Cap ETF | 39.72K | 33.62K | 0.09% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 29.14K | 24.67K | 0.07% |
| 2024-07-30 | DFA U.S. Small Cap Series | 23.58K | 19.96K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 13 | 2025-04-09 |
| 1 : 15 | 2021-06-28 |
| 1 : 15 | 2021-06-25 |
| 1 : 15 | 2018-12-10 |